HONOR-B (02256.HK) Announces Results of Two Pre-Clinical Trials of Subsidiary Shanghai and Reputation Biomedical Technologies in Spain in October
Announced at the 36th International Conference on Molecular Targeting and Cancer Treatment (ENA) in Barcelona.
According to the above two studies, the results of the above study demonstrate the latest pre-clinical research progress of the drug “PRMT5*MTA inhibitor ABSK131” and the “oral KRASG12D small molecule inhibitor ABSK141”, respectively, in the research pipeline. (js/w)
~